International Journal of Infectious Diseases, 2023 Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low +12 more
doaj +1 more source
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life [PDF]
, 2023 Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines.
Francesca Larese Filon +4 more
core +1 more source
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection [PDF]
, 2023 Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection.
Bartoletti M. +16 more
core +1 more source
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
Scientific Reports, 2023 We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon +9 more
doaj +1 more source
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Antibiotics, 2022 Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir ...
Yuan-Pin Hung +6 more
doaj +1 more source
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]
, 2022 BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori +24 more
core +2 more sources
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs.
Ayumi Tsuzawa +11 more
doaj +1 more source
Drug-drug interaction with oral antivirals for the early treatment of COVID-19 [PDF]
, 2022 Non peer ...
Kovanen, Petri T. +2 more
core +2 more sources
Antivirals for the treatment of mild and moderate COVID-19 in South Africa [PDF]
, 2023 While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services.
Gengiah, T N +3 more
core +2 more sources
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
Infection and Drug Resistance, 2023 Cheng-Yi Hu,1 Wen-Shuai Cui,1 Yi Lei,1 Yu-Wen Tang,1 Yan-Yan Zhang,1 Qi-Min Su,1 Fang Peng,2 Yun-Fei Zeng,1 Jia-Lin Song,1 Cheng-Na Luo,1 Yan Zhou,1 Xin-Yan Li,1 Zhu-Xiang Zhao1 1Department of Infectious Diseases, Guangzhou First People’s Hospital ...
Hu CY +12 more
doaj